These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28487953)

  • 1. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
    Zhou J; Zhang C; Pan J; Chen L; Qi ST
    Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma.
    Li W; Zhang Y; Zhuang Y; Chen R; Xiong Z; Li K; Liu F; Xu H; Li D; Peng J
    Neuroendocrinology; 2024; 114(10):934-949. PubMed ID: 38964285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma.
    Chen M; Zheng SH; Liu Y; Shi J; Qi ST
    J Neurol Sci; 2016 Jan; 360():49-54. PubMed ID: 26723972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
    Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
    Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
    Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
    Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
    Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
    J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis?
    Song-Tao Q; Xiao-Rong Y; Jun P; Yong-Jian D; Jin L; Guang-Long H; Yun-Tao L; Jian R; Xiang-Zhao L; Jia-Ming X
    Histopathology; 2014 Feb; 64(3):336-47. PubMed ID: 24387671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calretinin is expressed in the stroma of adamantinomatous craniopharyngioma and may induce calcification.
    Chaohu W; Yi L; Hai H; Hui Z; Jun P; Song-Tao Q
    Clin Neurol Neurosurg; 2015 Nov; 138():124-8. PubMed ID: 26319618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
    Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
    J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
    Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
    J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
    Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
    Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
    Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
    Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition and clinicopathological correlation in craniopharyngioma.
    Qi ST; Zhou J; Pan J; Zhang C; Silky C; Yan XR
    Histopathology; 2012 Oct; 61(4):711-25. PubMed ID: 23551434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1α leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis.
    Mao J; Qiu B; Mei F; Liu F; Feng Z; Fan J; Nie J; Huang L; Liao X; Wang Z; Zeng J; Weng Z; Zang N; Qi S; Bao Y
    Metabolism; 2019 Dec; 101():153998. PubMed ID: 31666193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression pattern of inflammatory cytokines at various inflammatory levels of adamantinomatous craniopharyngioma].
    Zhou J; Qi ST; Chen LG; Huang CR; You J; Zhang C; Pan J
    Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2499-501. PubMed ID: 24300275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblastic differentiation and cell calcification of adamantinomatous craniopharyngioma induced by bone morphogenetic protein-2.
    Yan X; Kang D; Pan J; Jiang C; Lin Y; Qi S
    Cancer Biomark; 2017; 18(2):191-198. PubMed ID: 27983534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children.
    Gong J; Zhang H; Xing S; Li C; Ma Z; Jia G; Hu W
    Cancer Biomark; 2014; 14(4):241-51. PubMed ID: 24934367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.